Curcumin and long chain omega-3 fatty acids for management of cardiovascular health in individuals with type 2 diabetes

INTERVENTION: Study participants will be randomly allocated to these treatment arms for 6 weeks 1) 2 X placebo tablets (matching for curcumin) + 2 X placebo capsules (matching for fish oil) per day 2) 2 X 500 mg curcumin tablets + 2 X placebo capsules (matching for fish oil) per day 3) 2 X 1000 mg fish oil capsules + 2 X placebo tablets (matching for curcumin) per day 4) 2 X 500 mg curcumin tablets + 2 X 1000 mg fish oil capsules per day To monitor adherence to intervention, 1. Capsule intake by participants will be measured on post‐intervention visit 2. Compliance to the omega 3 fatty acids will be monitored by measuring participant's erythrocyte fatty acid content 3. Adherence to curcumin will be monitored by measuring curcumin content in the participant blood sample by using HPLC method. CONDITION: Type 2 Diabetes PRIMARY OUTCOME: Serum Triglycerides ; Serum Triglycerides will be analyzed by Hunter New England Area Pathology Services (HAPS) SECONDARY OUTCOME: C‐Reactive protein in blood sample Analysed by Hunter New England Area Pathology Services (HAPS) Fasting LDL cholesterol in blood sample Analysed by Hunter New England Area Pathology Services (HAPS) Fasting plasma glucose levels Analysed by Hunter New England Area Pathology Services (HAPS) Fasting plasma insulin levels Analysed by Hunter New England Area Pathology Services (HAPS) Serum Adiponectin (ELISA method) Serum HDL‐Cholesterol ; Serum HDL‐Cholesterol will be analyzed by Hunter New England Area Pathology Services (HAPS) Serum Total cholesterol ; Serum Total cholesterol will be analyzed by Hunter New England Area Pathology Services (HAPS) ; INCLUSION CRITERIA: This study is suitable for you if You are aged between 40 and 75 years; You are diagnosed with type 2 diabetes (duration less than 15 years) Your body mass index (BMI) lies between 25 and 45 kg/m2